News & Updates

Higher SUA to creatinine ratio ups risk of pre-eclampsia, adverse pregnancy outcomes

During pregnancy, a higher serum uric acid (SUA) to creatinine (sCr) ratio appears to elevate the risk of pre-eclampsia (PE) and adverse pregnancy outcomes, suggests a recent study.

Fitusiran cuts bleeding in haemophilia patients regardless of inhibitor use

In the phase III ATLAS-PPX trial, the investigational siRNA* therapeutic fitusiran significantly cut bleeding events compared with factor/bypassing agent (BPA) prophylaxis in patients with haemophilia A or B with or without inhibitors.

PNH carries a high disease burden despite treatment

Paroxysmal nocturnal haemoglobinuria (PNH) carries a substantial disease burden and healthcare resource utilization, even in patients already receiving treatment with C5 inhibitors, according to an expert who presented at EHA 2023.

Tranexamic acid use before CS reduces blood loss

The use of prophylactic tranexamic acid (TXA) prior to elective Caesarean section (CS) led to significantly lower blood loss in women, particularly those at high risk for postpartum haemorrhage (PPH), according to a study presented at RCOG 2023.

OSA treatment with positive airway pressure reduces economic burden in HFpEF

In patients with heart failure with preserved ejection fraction (HFpEF) and comorbid obstructive sleep apnoea (OSA), positive airway pressure (PAP) therapy helps lower the use of healthcare resource, according to a study.

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

The FLT3 type II inhibitor quizartinib, when combined with induction and consolidated therapy and continued for up to 12 cycles, yields survival benefits such as prolonged overall and relapse-free survival in patients with newly diagnosed wild-type acute myeloid leukaemia (AML), as shown in the interim results of the phase II study QUIWI.

Does acute kidney injury lead to CKD progression?

Mild to moderate acute kidney injury (AKI) is slightly associated with worsening subsequent kidney function in patients with chronic kidney disease (CKD) following adjustments for pre-AKI estimated glomerular filtration rate (eGFR), proteinuria, and other covariables, with the possibility of no correlation, suggests a study.